SI-BONE, Inc. (NASDAQ:SIBN) Shares Bought by Champlain Investment Partners LLC

Champlain Investment Partners LLC increased its position in shares of SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 14.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,800,073 shares of the company's stock after purchasing an additional 358,821 shares during the period. Champlain Investment Partners LLC owned 6.72% of SI-BONE worth $39,145,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of SIBN. Harbor Capital Advisors Inc. grew its stake in shares of SI-BONE by 222.5% during the third quarter. Harbor Capital Advisors Inc. now owns 620,490 shares of the company's stock worth $8,674,000 after purchasing an additional 428,110 shares in the last quarter. American Century Companies Inc. lifted its position in SI-BONE by 22.8% in the second quarter. American Century Companies Inc. now owns 1,986,476 shares of the company's stock valued at $25,685,000 after acquiring an additional 368,637 shares during the last quarter. Paradigm Capital Management Inc. NY lifted its position in SI-BONE by 24.7% in the second quarter. Paradigm Capital Management Inc. NY now owns 1,349,400 shares of the company's stock valued at $17,448,000 after acquiring an additional 267,100 shares during the last quarter. Impax Asset Management Group plc lifted its position in SI-BONE by 41.3% in the third quarter. Impax Asset Management Group plc now owns 758,521 shares of the company's stock valued at $10,604,000 after acquiring an additional 221,604 shares during the last quarter. Finally, Pier Capital LLC lifted its position in SI-BONE by 80.7% in the second quarter. Pier Capital LLC now owns 377,001 shares of the company's stock valued at $4,875,000 after acquiring an additional 168,417 shares during the last quarter. Institutional investors and hedge funds own 98.11% of the company's stock.

SI-BONE Stock Performance

Shares of NASDAQ:SIBN traded up $0.27 on Friday, reaching $12.56. The company's stock had a trading volume of 265,344 shares, compared to its average volume of 515,091. The stock's 50-day moving average is $13.72 and its two-hundred day moving average is $14.21. SI-BONE, Inc. has a 52-week low of $11.70 and a 52-week high of $21.70. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. The stock has a market capitalization of $526.77 million, a P/E ratio of -13.65 and a beta of 1.22.

Insider Activity

In related news, insider Anthony J. Recupero sold 3,305 shares of the stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $13.58, for a total transaction of $44,881.90. Following the completion of the transaction, the insider now directly owns 233,412 shares of the company's stock, valued at $3,169,734.96. This represents a 1.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Laura Francis sold 10,048 shares of the stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $12.58, for a total transaction of $126,403.84. Following the transaction, the chief executive officer now directly owns 482,875 shares of the company's stock, valued at $6,074,567.50. This represents a 2.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 23,093 shares of company stock valued at $299,558. Insiders own 3.90% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Needham & Company LLC reissued a "buy" rating and issued a $19.00 price target on shares of SI-BONE in a research report on Wednesday. Morgan Stanley reduced their price target on shares of SI-BONE from $21.00 to $19.00 and set an "overweight" rating for the company in a research report on Tuesday, August 6th. Finally, Truist Financial boosted their price target on shares of SI-BONE from $16.00 to $18.00 and gave the company a "buy" rating in a research report on Wednesday, November 13th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $23.00.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.